About One in Six Readmitted Post-Revascularization for PAD

Share this content:
About One in Six Readmitted Post-Revascularization for PAD
About One in Six Readmitted Post-Revascularization for PAD

TUESDAY, Dec. 5, 2017 (HealthDay News) -- For patients with peripheral arterial disease who are discharged following peripheral arterial revascularization, 17.6 percent have 30-day nonelective readmission, according to a study published online Dec. 5 in the Annals of Internal Medicine.

Eric A. Secemsky, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues examined readmissions after peripheral arterial revascularization for peripheral arterial disease in a retrospective cohort study. Data were included for 61,969 unweighted hospitalizations of patients with peripheral arterial disease who were discharged from 1,085 U.S. acute care hospitals.

The researchers found that the 30-day elective readmission rate was 17.6 percent among patients discharged alive after peripheral arterial revascularization. The most common causes of readmission were procedural complications, sepsis, and complications due to diabetes mellitus (28.0, 8.3, and 7.5 percent). Twenty-one percent of rehospitalized patients underwent a subsequent peripheral arterial revascularization or lower extremity amputation and 4.6 percent died. Readmission had a median cost of $11,013. There was variation in the 30-day risk-standardized readmission rates between hospitals, from 10.0 to 27.3 percent.

"More than one in six patients with peripheral arterial disease who undergo peripheral arterial revascularization have unplanned readmission within 30 days, with high associated mortality risks and costs," the authors write.

Several authors disclosed financial ties to the pharmaceutical and health care industries.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »